Biotech Stocks To Watch Archives

Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus

Mar 8, 2021Biotech (General), Biotech Stocks To Watch

STAMFORD, Conn, and ST. GALLEN, Switzerland, March 08, 2021 (GLOBE NEWSWIRE) — Cara Therapeutics (Nasdaq:CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The […]

Takeda takes full control of drug for rare epilepsies

Mar 4, 2021Biotech (General), Biotech Stocks To Watch

Takeda, the world’s largest developer of rare disease drugs, said Tuesday that it has reclaimed full rights to an experimental medicine being tested against uncommon forms of epilepsy. The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, […]

FDA APPROVES FIRST-IN-CLASS EVKEEZA™ (EVINACUMAB-DGNB) FOR PATIENTS WITH ULTRA-RARE INHERITED FORM OF HIGH CHOLESTEROL

Feb 22, 2021Biotech (General), Biotech Stocks To Watch, Hypercholesterolemia

Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. and is characterized by extremely high low-density lipoprotein cholesterol (LDL-C) In pivotal Phase 3 HoFH trial, adding Evkeeza to standard lipid-lowering therapies reduced LDL-C by nearly half at 24 weeks, compared to placebo Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. […]

Horizon inks $3B deal to buy AstraZeneca spinout Viela for autoimmune drugs

Feb 2, 2021Biotech (General), Biotech Stocks To Watch, Corporate News

Horizon Therapeutics has struck a $3 billion deal to buy AstraZeneca spinout Viela Bio. The takeover will give Horizon a clutch of clinical-phase autoimmune and inflammatory disease drug candidates, R&D capabilities and an approved monoclonal antibody. Viela spun out of AstraZeneca with six drug candidates and $250 million early in 2018. Since then, the biotech has gone […]

Vir stock soars on blinded, 8-subject hepatitis B analysis

Jan 28, 2021Biotech (General), Biotech Stocks To Watch, Hepatitis B

Shares in Vir Biotechnology rose 74% on the strength of data from a blinded, eight-subject cohort in its phase 1 hepatitis B trial. The analysis suggests the neutralizing monoclonal antibody may be more potent than expected and provides a boost to Vir’s prospects of delivering a functional cure. Investigators enrolled eight patients with chronic hepatitis B virus […]

Is Sorrento Therapeutics Stock a Buy?

Oct 25, 2020Biotech (General), Biotech Stocks To Watch, COVID-19

Back in May, Sorrento Therapeutics (NASDAQ:SRNE) captivated investor attention after it claimed the discovery of an antibody that can provide “100% inhibition” against COVID-19. In fact, the company’s senior vice president, Dr. Mark Brunswick, made the following statement in an interview by Fox News: “So, if we were approved [by the U.S. Food and Drug […]

REGENERON’S ANTIBODY COCKTAIL REGN-EB3 (INMAZEB®) IS FIRST FDA-APPROVED TREATMENT FOR EBOLA (ZAIRE EBOLAVIRUS)

Oct 25, 2020Biotech (General), Biotech Stocks To Watch, Corporate News

In a large clinical trial, Inmazeb showed superiority compared to other investigational agents (ZMapp and remdesivir) with respect to mortality; treatment was most effective when given early in the course of disease1 Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) is a novel anti-viral antibody medicine developed using the same ‘rapid response’ technologies as Regeneron’s investigational COVID-19 antibody […]

Japan Grants Patent to Brainstorm Covering Technique for NurOwn

Sep 25, 2020ALS, Biotech (General), Biotech Stocks To Watch, Clinical Trials, Corporate News, Multiple Sclerosis

The Japan Patent Office has granted a patent to Brainstorm Cell Therapeutics covering the proprietary technique that generates the company’s cell-based therapy NurOwn from mesenchymal stem cells (MSCs). Through this technique, researchers can harness MSCs directly from a patient and mature them into cells that produce high levels of neurotrophic factors, which are compounds that […]

Regeneron’s Praluent sidekick nabs speedy FDA review, with February PDUFA date

Aug 12, 2020Biotech (General), Biotech Stocks To Watch

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab. Patients with high cholesterol from a rare genetic disorder struggle to keep their cholesterol levels in check, despite taking multiple lipid-busting drugs. A new drug from Regeneron may change […]

Bausch Health Announces Its Intention To Spin Off Its Eye Health Business Into An Independent Publicly Traded Company

Aug 7, 2020Biotech (General), Biotech Stocks To Watch, Corporate News

LAVAL, QC, Aug. 6, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) today announced that it intends to spin off its leading eye health business into an independent publicly traded entity (“Bausch + Lomb – NewCo”) from the remainder of Bausch Health (“BHC”). The spinoff will establish two separate […]